de Jong RS - Search Results

1

[Eosinophilia caused by solid malignancy].

Niamut SM, de Vries PA, van Putten JW, de Jong RS. Niamut SM, et al. Among authors: de jong rs, de vries pa. Ned Tijdschr Geneeskd. 2004 Sep 18;148(38):1883-6. Ned Tijdschr Geneeskd. 2004. PMID: 15497785 Dutch.

2

[2 patients with a non-Hodgkin lymphoma located in the pancreas].

de Jong RS, Damen RM, Westerveld BD, Nelis GF. de Jong RS, et al. Ned Tijdschr Geneeskd. 1992 Feb 29;136(9):432-4. Ned Tijdschr Geneeskd. 1992. PMID: 1542369 Dutch.

3

Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.

de Jong RS, Mulder NH, Uges DR, Sleijfer DT, Höppener FJ, Groen HJ, Willemse PH, van der Graaf WT, de Vries EG. de Jong RS, et al. Among authors: de vries eg. Br J Cancer. 1999 Feb;79(5-6):882-7. doi: 10.1038/sj.bjc.6690141. Br J Cancer. 1999. PMID: 10070885 Free PMC article. Clinical Trial.

4

A 71-yr-old male with increasing dyspnoea, cough and an intrathoracic mass.

Seebus E, Vrugt B, de Jong RS, Aalbers R. Seebus E, et al. Among authors: de jong rs. Eur Respir J. 2003 Dec;22(6):1042-5. doi: 10.1183/09031936.03.00020303. Eur Respir J. 2003. PMID: 14680097 Free article. No abstract available.

5

Trastuzumab and bevacizumab combined with docetaxel, oxaliplatin and capecitabine as first-line treatment of advanced HER2-positive gastric cancer: a multicenter phase II study.

Meulendijks D, Beerepoot LV, Boot H, de Groot JW, Los M, Boers JE, Vanhoutvin SA, Polee MB, Beeker A, Portielje JE, de Jong RS, Goey SH, Kuiper M, Sikorska K, Beijnen JH, Tesselaar ME, Schellens JH, Cats A. Meulendijks D, et al. Among authors: de jong rs. Invest New Drugs. 2016 Feb;34(1):119-28. doi: 10.1007/s10637-015-0309-4. Epub 2015 Dec 8. Invest New Drugs. 2016. PMID: 26643663 Clinical Trial.

6

Phase II study of intraperitoneal cisplatin plus systemic etoposide as second-line treatment in patients with small volume residual ovarian cancer.

de Jong RS, Willemse PH, Boonstra H, de Vries EG, van der Graaf WT, Sleijfer DT, van der Zee AG, Mulder NH. de Jong RS, et al. Among authors: de vries eg. Eur J Cancer. 1995;31A(5):709-13. doi: 10.1016/0959-8049(94)00516-8. Eur J Cancer. 1995. PMID: 7640042 Clinical Trial.

7

Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.

de Jong RS, Mulder NH, Uges DR, Kaul S, Winograd B, Sleijfer DTh, Groen HJ, Willemse PH, van der Graaf WT, de Vries EG. de Jong RS, et al. Among authors: de vries eg. Br J Cancer. 1997;75(11):1660-6. doi: 10.1038/bjc.1997.282. Br J Cancer. 1997. PMID: 9184183 Free PMC article. Clinical Trial.

8

Fostriecin: a review of the preclinical data.

de Jong RS, de Vries EG, Mulder NH. de Jong RS, et al. Among authors: de vries eg. Anticancer Drugs. 1997 Jun;8(5):413-8. Anticancer Drugs. 1997. PMID: 9215602 Review.

9

Conversion of the prodrug etoposide phosphate to etoposide in gastric juice and bile.

de Jong RS, Slijfer EA, Uges DR, Mulder NH, de Vries EG. de Jong RS, et al. Among authors: de vries eg. Br J Cancer. 1997;76(11):1480-3. doi: 10.1038/bjc.1997.581. Br J Cancer. 1997. PMID: 9400945 Free PMC article.

10

Renal toxicity of the anticancer drug fostriecin.

de Jong RS, de Vries EG, Meijer S, de Jong PE, Mulder NH. de Jong RS, et al. Among authors: de vries eg, de jong pe. Cancer Chemother Pharmacol. 1998;42(2):160-4. doi: 10.1007/s002800050800. Cancer Chemother Pharmacol. 1998. PMID: 9654117

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

29 results

Search Page

Filters